Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4045/tidsskr.19.0796 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Impact of decentralized management on sickness absence in hospitals: a two-wave cohort study of frontline managers in Danish hospital wards.
BMC Health Serv Res
July 2024
Department of Technology and Innovation, University of Southern Denmark, Odense, Denmark.
Background: This study explores the impact of decentralized management on the sickness absence among healthcare professionals. Sickness absence is a reliable indicator of employees' wellbeing and it is linked to management quality. However, the influence of decentralized management on sickness absence has not been adequately studied.
View Article and Find Full Text PDFPatient- and parent-reported diagnostic delay in children with central nervous system tumors in Denmark.
Pediatr Blood Cancer
August 2024
Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
Background: Diagnostic delays in childhood tumors of the central nervous system (CNS) pose a significant challenge. The aim of this study was to map diagnostic delay and presenting symptoms in Denmark.
Methods: The study was a retrospective questionnaire study, mapping delay and symptoms in pediatric patients (0-17 years), diagnosed with a CNS tumor from 2015 to 2019.
An accidental encounter with bloom of diatom Palmerina hardmaniana (Greville) Hasle in Sundarbans, India: Impact on zooplankton community structure in tidal creek environment.
Mar Pollut Bull
February 2024
School of Oceanographic Studies, Jadavpur University, Jadavpur, Kolkata, India.
The present study reports on a transient diatom bloom of Palmerina hardmaniana (Greville) Hasle 1996 encountered accidentally in May 2018 in the world's largest mangrove forest of Sundarbans, India. This bloom was the sixth record of diatom blooms from Indian coastal waters and the fourth from Sundarbans waters. The diatom cell count ranged from 2.
View Article and Find Full Text PDFAzacitidine (Vidaza) in Pediatric Patients with Relapsed Advanced MDS and JMML: Results of a Phase I/II Study by the ITCC Consortium and the EWOG-MDS Group (Study ITCC-015).
Paediatr Drugs
November 2023
Department of Pediatric Oncology, Princess Maxima Center for Pediatric Oncology, Utrecht, The Netherlands.
Background: Advanced myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML) are rare hematological malignancies in children. A second allograft is recommended if a relapse occurs after hematopoietic stem cell transplantation, but the outcome is poor.
Objective: We conducted a phase I/II multicenter study to evaluate the safety, pharmacokinetics, and activity of azacitidine in children with relapsed MDS/JMML prior to the second hematopoietic stem cell transplantation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!